Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
TLDR
In this article, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET), and the equivalent emergence of primary myelofibrosis (PMF).Abstract:
Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling of the bone marrow niche in a manner that promotes malignant over non-malignant hematopoiesis. This take-over of hematopoiesis by the malignant clone is hypothesized to include hyperactivation of inflammatory signaling and overproduction of inflammatory cytokines. In the Ph-negative MPNs, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET) to secondary myelofibrosis (MF), and the equivalent emergence of primary myelofibrosis (PMF). Bone marrow fibrosis itself is thought to be mediated heavily by the cytokine TGF-β, and possibly other cytokines produced as a result of hyperactivated JAK2 kinase in the malignant clone. MF also features extramedullary hematopoiesis and progression to bone marrow failure, both of which may be mediated in part by responses to cytokines. In MF, elevated levels of individual cytokines in plasma are adverse prognostic indicators: elevated IL-8/CXCL8, in particular, predicts risk of transformation of MF to secondary AML (sAML). Tumor necrosis factor (TNF, also known as TNFα), may underlie malignant clonal dominance, based on results from mouse models. Human PV and ET, as well as MF, harbor overproduction of multiple cytokines, above what is observed in normal aging, which can lead to cellular signaling abnormalities separate from those directly mediated by hyperactivated JAK2 or MPL kinases. Evidence that NFκB pathway signaling is frequently hyperactivated in a pan-hematopoietic pattern in MPNs, including in cells outside the malignant clone, emphasizes that MPNs are pan-hematopoietic diseases, which remodel the bone marrow milieu to favor persistence of the malignancy. Clinical evidence that JAK2 inhibition by ruxolitinib in MF neither reliably reduces malignant clonal burden nor eliminates cytokine elevations, suggests targeting cytokine mediated signaling as a therapeutic strategy, which is being pursued in new clinical trials. Greater knowledge of inflammatory pathophysiology in MPNs can therefore contribute to the development of more effective therapy.read more
Citations
More filters
Journal ArticleDOI
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Lionel Ades,Larisa Girshova,Vadim A Doronin,María Díez-Campelo,David Valcárcel,Suman Kambhampati,Nora Viniou,Dariusz Woszczyk,R. de Paz Arias,Argiris Symeonidis,Achilles Anagnostopoulos,Eduardo Munhoz,Uwe Platzbecker,Valeria Santini,Robert Fram,Ying Yuan,Sharon Friedlander,Douglas V. Faller,Mikkael A. Sekeres +18 more
TL;DR: The results underscore the importance of large, randomized controlled trials in these heterogeneous myeloid diseases and the value of remaining on therapy >3 cycles.
Journal ArticleDOI
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
TL;DR: In this paper , the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts.
Journal ArticleDOI
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Naveen Pemmaraju,Jacqueline S. Garcia,Jalaja Potluri,Jason G. Harb,Yan Sun,P. Soo Jung,Q. Qin,Srinivas K. Tantravahi,Srdan Verstovsek,Claire N. Harrison +9 more
TL;DR: This article showed that the addition of navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume (SVR35) and reduced symptoms in patients with myelofibrosis no longer benefiting from ruxolaxinib.
Journal ArticleDOI
Defining disease modification in myelofibrosis in the era of targeted therapy
TL;DR: In this article , the authors discuss recent clinical trial data of agents in development and dissect the potential for novel end points to act as disease modifying parameters, using the rationale garnered from latest clinical and scientific evidence, the authors propose a definition of disease modification in myelofibrosis.
Journal ArticleDOI
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Srdan Verstovsek,Haifa Kathrin Al-Ali,John Mascarenhas,Andrew C. Perkins,Alessandro M. Vannucchi,Sanjay R. Mohan,Bart L. Scott,Dariusz Woszczyk,Steffen Koschmieder,Regina Garcia-Delgado,Rejtő László,Jesse McGreivy,Wayne Rothbaum,Jean-Jacques Kiladjian +13 more
TL;DR: Navtemadlin (KRT-232) as mentioned in this paper restores p53 activity to drive apoptosis of wild-type TP53 tumor cells by inducing expression of pro-apoptotic Bcl-2 family proteins.
References
More filters
Journal ArticleDOI
Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia.
Genta Ishikawa,Naoto Fujiwara,Naoto Fujiwara,Hadassa Hirschfield,Lilian Varricchio,Yujin Hoshida,Yujin Hoshida,Giovanni Barosi,Vittorio Rosti,Maria Padilla,Maria Mazzarini,Scott L. Friedman,Ronald Hoffman,Anna Rita Migliaccio +13 more
TL;DR: TGF-β is identified as a potential target for micro-environmental therapy in primary myelofibrosis patients, the Philadelphia-negative myeloproliferative neoplasm associated with the poorest prognosis.
Journal ArticleDOI
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms
Patrizia Mondello,Patrizia Mondello,Cristian Di Mirto,Salvatore Cuzzocrea,Carmela Arrigo,Michael Mian,Vincenzo Pitini +6 more
TL;DR: The data support IFN-α as a more valid therapeutic option owing to its more profound hematologic responses, durable molecular remissions, long-term disease control, and reduced risk of leukemic transformation with a favorable toxicity profile.
Journal ArticleDOI
Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera.
TL;DR: The mutational profile of PVyoung may differ from PVold and potentially contribute to distinct clinical phenotypes observed in these cohorts, and a trend toward more females and SVT events in the PVyoung group was observed.
Journal ArticleDOI
Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation.
Giovanni Barosi,Rita Campanelli,Paolo Catarsi,Mara De Amici,Carlotta Abbà,Gianluca Viarengo,Laura Villani,Robert Peter Gale,Vittorio Rosti,Margherita Massa +9 more
Journal ArticleDOI
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms
Debra Van Egeren,Javier Escabi,Maximilian Nguyen,Shichen Liu,Christopher R. Reilly,Sachin Patel,Baransel Kamaz,Maria Kalyva,Daniel J. DeAngelo,Ilene Galinsky,Martha Wadleigh,Eric S. Winer,Marlise R. Luskin,Richard Stone,Jacqueline S. Garcia,Gabriela S. Hobbs,Fernando D. Camargo,Franziska Michor,Ann Mullally,Ann Mullally,Isidro Cortes-Ciriano,Sahand Hormoz +21 more
TL;DR: The studies suggest that the JAK2V617F mutation alone is sufficient to initiate and engender MPN, which has important therapeutic implications, and indicates that theJAK2-mutant clone may manifest as clonal hematopoiesis of indeterminate potential (CHIP) for a decade or more before presenting as an overt MPN.